Adults 18 to 70, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants and Type of Reported Adverse EventsPrimary· Up to 2,5 years from begin of study
Determine the safety of the administration of TIL therapy including checkpoint inhibitors, lymphodepleting chemotherapy and Interleukin-2 for patients with cancer by reporting grade \>2 adverse events according to CTCAE v. 4.0
Neutropenia
Group
Value
95% CI
All Participants
25
Trombocytopenia
Group
Value
95% CI
All Participants
22
Anemia
Group
Value
95% CI
All Participants
22
Infection
Group
Value
95% CI
All Participants
6
Hyponatremia
Group
Value
95% CI
All Participants
2
Hemorrhagic cystitis
Group
Value
95% CI
All Participants
1
Fatique
Group
Value
95% CI
All Participants
6
Vertigo
Group
Value
95% CI
All Participants
1
Time to Disease ProgressionSecondary· Until study completion
Days of follow-up from TIL infusion until progressive cancer disease, end of follow-up or death.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Group
Value
95% CI
Treated Participants
89
12 – 211
Overall SurvivalSecondary· Until study completion
Duration of survival measured in days after adoptive cell therapy until death or end of follow-up/censoring.
Group
Value
95% CI
Treated Participants
227
50 – 870
Overall Response RateSecondary· The patients were evaluated every 6-12 weeks (median 90 days) and after therapy and until study completion (max 220 days).
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CAT scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Group
Value
95% CI
Treated Participants
2
Adverse events — posted to ClinicalTrials.gov
Time frame: The data was collected throughout the duration of the clinical trial. From October 2017 and until study Completion in july, 2020. For the individual patient, the reporting started at the study enrolment and ended with study exclusion but with a minimum of 6 months follow-up after the adoptive cell therapy or until study completion. Information on adverse events were collected every 6 weeks for the first 3 months and every 3 months hereafter..
Reporting threshold: 4%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study will perform tumor-infiltrating lymphocyte (TIL)-based adoptive T-cell therapy in combination with checkpoint inhibition on cancer patients across all cancer diagnoses.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Other trials of Autologous tumor-infiltrating lymphocytes
Trials testing the same drug.
NCT05152797 — Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer
· Phase 1, PHASE2
· not yet recruiting
Other recruiting trials for Cancer
Currently open trials in the same condition.
NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors
· NA
· recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy
· NA
· recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients.
· NA
· recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations
· NA
· recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
· NA
· recruiting
Other Inge Marie Svane trials
Trials by the same sponsor.
NCT07501117 — Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
· Phase 1
· not yet recruiting
NCT06204991 — To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
· Phase 1
· recruiting
NCT06783270 — T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
· Phase 1
· recruiting
NCT04904185 — ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
· Phase 1
· terminated
NCT04611126 — T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
· Phase 1, PHASE2
· terminated
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inge Marie Svane
Last refreshed: 26 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03296137.